Transplantation
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 53 Shown
  • How I Expect Evolving Options for HCV Therapy Will Affect Posttransplant Management

    Paul Y. Kwo MD - 7/29/2015 1 comment / Last Comment: 10/10/2015
    Will we finally have options to prevent posttransplantation HCV recurrence across the spectrum of genotypes?
  • Learning Module

    Highlights From EASL 2015: HCV Management

    In this Expert Analysis, Jordan J. Feld, MD, MPH; David R. Nelson, MD; and Stefan Zeuzem, MD, provide a comprehensive review of the most significant data on the management of hepatitis C presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
    Faculty: Jordan J. Feld MD, MPH, David R. Nelson MD, Stefan Zeuzem MD
    Released: 6/29/2015
  • Highlights From EASL: HCV Approved Therapies

    In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
    Date Posted: 5/11/2015
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015 3 comments / Last Comment: 7/26/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • When Should Patients on the Liver Transplant Waitlist Receive HCV Therapy?

    John Roberts MD - 4/24/2015 5 comments / Last Comment: 8/27/2016
    Now that highly tolerable, highly effective HCV treatments are available, treatment in the pretransplant setting is a viable approach for many patients currently on the waitlist. Does this approach have a downside?
  • HCV Treatment in Liver Transplantation Recipients: My Take on the Latest HCV Guidance

    Nezam H. Afdhal MD, FRCPI - 4/7/2015 2 comments / Last Comment: 6/3/2015
    In starting HCV treatment after liver transplant, how soon is soon enough?
  • Redefining Best Practices in HCV Management in the Transplant Setting

    In this downloadable slideset, Norah Terrault, MD, MPH, leads a review of a series of cases with Jean C. Emond, MD, and Paul Y. Kwo, MD, evaluating the optimal use of available HCV therapies in the pretransplantation and posttransplantation patients.
    Date Posted: 9/16/2014
  • Key Challenges in HCV Management in the Transplant Setting

    In this downloadable slideset, Jean C. Edmond, MD, offers insight into managing HCV in pretransplant and posttransplant patients.
    Date Posted: 9/15/2014
  • Interferon-Free HCV Therapy in the Transplant Setting

    In this downloadable slideset, Paul Y. Kwo, MD, reviews current and forthcoming options for interferon-free treatment of pretransplantation and posttransplantation patients with HCV.
    Date Posted: 9/15/2014
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014 5 comments / Last Comment: 6/4/2015
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
10 of 53 Shown
Show 10 More
Loading...